Table 3.
Risk factors for TNF inhibitor discontinuation in RA patients
| Total RA | Elderly patients | Young RA | ||||
|---|---|---|---|---|---|---|
| Adjusted HR (95 % CI) | p | Adjusted HR (95 % CI) | p | Adjusted HR (95 % CI) | p | |
| Age at start of biologics | 1.00 (0.99 – 1.02) | 0.66 | 1.09 (1.02 – 1.16) | <0.01 | 1.00 (0.99 – 1.02) | 0.64 |
| Sex, female | 1.06 (0.65 – 1.74) | 0.81 | 1.81 (0.64 – 5.12) | 0.27 | 0.84 (0.47 – 1.49) | 0.55 |
| Switcher vs. first user | 0.55 (0.35 – 0.86) | <0.01 | 0.43 (0.16 – 1.22) | 0.11 | 0.57 (0.34 – 0.94) | 0.03 |
| Disease duration, per year | 0.97 (0.95 – 0.997) | 0.03 | 0.96 (0.91 – 1.00) | 0.05 | 0.97 (0.94 – 0.997) | 0.03 |
| Biologics | ||||||
| Etanercept | 1.00 | 1.00 | 1.00 | |||
| Infliximab | 1.44 (0.92 – 2.27) | 0.11 | 0.43 (0.10 – 1.97) | 0.28 | 1.81 (1.11 – 2.95) | 0.02 |
| Adalimumab | 0.88 (0.59 – 1.32) | 0.54 | 0.72 (0.30 – 1.74) | 0.46 | 0.86 (0.54 – 1.37) | 0.53 |
| Concomitant use of methotrexate | 0.72 (0.51 – 1.01) | 0.06 | 0.44 (0.21 – 0.91) | 0.03 | 0.91 (0.62 – 1.35) | 0.64 |
| Concomitant glucocorticoid dosage | ||||||
| <5 mg/day | 1.00 | 1.00 | 1.00 | |||
| ≥5 mg/day | 1.05 (0.76 – 1.46) | 0.75 | 1.18 (0.53 – 2.62) | 0.68 | 0.97 (0.67 – 1.41) | 0.89 |
| Comorbiditya | 0.91 (0.64 – 1.29) | 0.59 | 0.37 (0.15 – 0.91) | 0.03 | 1.04 (0.71 – 1.52) | 0.83 |
TNF tumor necrosis factor, HR hazard ratio, CI confidence interval, RA rheumatoid arthritis
aComorbidity: the presence of a comorbid condition
Bold means statistical significant at the p < 0.05